🏛️ Verified NIH Record • Updated 2026-07-22

Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony (NCT07217899)

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: University of Michigan

🩺 Plain-English Summary (8th-Grade Level)

This research study is being done to learn what effect a single dose of calcium gluconate will have on blood loss at the time of cesarean delivery in pregnancy patients at high risk for uterine atony.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (14 items) and avoid the listed exclusions (22 items).

Location: University of Michigan — Ann Arbor, Michigan

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Non-English speaking
  • Antenatal suspicion for placenta accreta spectrum
  • History of allergic reaction to Calcium Gluconate
  • Patients with hypertensive disorder of pregnancy receiving Magnesium Sulfate for seizure prophylaxis
  • Underlying Renal Disease defined as Cr\>1.0
  • Known underlying cardiac condition
  • Cardiac glycosides (Digoxin) within two weeks for maternal or fetal indication
  • Treatment with a calcium channel blocker medication within 24 hours of screening
  • Hypertensive disorder necessitating intravenous antihypertensive medication within 24 hours of screening
  • Emergent case where study participation could impede care (judgement of obstetrician or anesthesiologist)
  • Known hypercalcemia

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

  • University of Michigan — Ann Arbor, Michigan

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗